Aprea Therapeutics (NASDAQ:APRE – Get Free Report) and Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability.
Valuation & Earnings
This table compares Aprea Therapeutics and Unicycive Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aprea Therapeutics | $580,000.00 | 25.75 | -$14.29 million | ($3.32) | -0.83 |
| Unicycive Therapeutics | $680,000.00 | 57.84 | -$30.54 million | ($1.19) | -0.35 |
Aprea Therapeutics has higher earnings, but lower revenue than Unicycive Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Analyst Ratings
This is a summary of current ratings and recommmendations for Aprea Therapeutics and Unicycive Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aprea Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Unicycive Therapeutics | 0 | 0 | 4 | 1 | 3.20 |
Aprea Therapeutics presently has a consensus target price of $15.50, indicating a potential upside of 463.64%. Unicycive Therapeutics has a consensus target price of $5.13, indicating a potential upside of 1,129.61%. Given Unicycive Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than Aprea Therapeutics.
Institutional & Insider Ownership
34.2% of Aprea Therapeutics shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 12.8% of Aprea Therapeutics shares are owned by insiders. Comparatively, 24.1% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Aprea Therapeutics and Unicycive Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aprea Therapeutics | -1,012.37% | -56.38% | -46.35% |
| Unicycive Therapeutics | N/A | N/A | -34.98% |
Summary
Unicycive Therapeutics beats Aprea Therapeutics on 14 of the 15 factors compared between the two stocks.
About Aprea Therapeutics
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
